Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: regadenoson

« Back to Dashboard

Summary for Generic Name: regadenoson

Tradenames:1
Patents:14
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1

Pharmacology for Ingredient: regadenoson

Clinical Trials for: regadenoson

Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab
Status: Recruiting Condition: Coronary Artery Disease

Regadenoson and Adenosine
Status: Completed Condition: Coronary Artery Disease

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Completed Condition: Coronary Artery Disease; Type 1 Diabetes Mellitus

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
Status: Recruiting Condition: Myocardial Blood Flow Reserve

A Phase II Trial of Regadenoson in Sickle Cell Anemia
Status: Recruiting Condition: Sickle Cell Anemia

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Status: Completed Condition: Ischemic Heart Disease

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Status: Completed Condition: Coronary Artery Disease

Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,133,879<disabled>Y<disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes7,655,637<disabled>YY<disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,536,150<disabled><disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,470,801<disabled><disabled>
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,183,226<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc